Universal Ibogaine — Fact Sheet (February 2022)

4 slides from Universal Ibogaine's fact sheet, February 2022

Slide 1: Company Overview and Key Stats
UL) (ii) & 3 a 8 © 2 G 2 @ 4 UNIVERSAL IBOGAINE Nick Karos Chief Executive Officer Greg Leavens, CPA, CA Chief Financial Officer Dr. lan Rabb Chief Clinics Officer Hirpal Hundial Director of Clinical Services Colleen Clandening Director, Operations Chief lan Campbell, MBA Chairman (Independent) Dr.
Slide 2: Corporate Structure
UNIVERSALIBOGAINE Corporate Structure Shares issued and outstanding Shares reserved for issuance: Options (Brokers and others) $0.10 to Aug 31, 2023 Options (Directors, Officers, and Key People) $0.25 S years Performance shares - CEO and Directors n/a note 2) Advisors warrants $0.25 Dec 31, 2024 Sha
Slide 3: Why Universal Ibogaine?
Ve hy UNIVERSALIBOGAINE ? Offers an opportunity to help tackle the scourge of addiction. We present an ethical, medically supervised and regulatory- sanctioned channel to participate in the PSYCHEDELICS space Our ibogaine “biotech” play is partially “de-risked” due to the real-world data/evidence ba
Slide 4: Pre-CTA Meeting and Milestones Timeline
--2021-- Q4 Pre-CTA Meeting CTA Submission NOL, Ph2/HPOC Initiation* *Human proof of concept study (usually aligned with a ph28 (phase) development stage) --2022-- Q4 (Onward) Ph2/HPOC Completion Ph2/HPOC Readout Special Access (or Ph3/pivotal Start) Pre-CTAY Meeting Clinic 3+ Licensing / Franchisin